Home/Smart Money/Paulson & Co
§ 13F · FUND PROFILE

Paulson & Co.

Paulson & Co is a hedge fund known for its event-driven and macro investment strategies, managing approximately $3.0 trillion in assets. The fund appears to maintain a concentrated portfolio with significant positions in companies like Madrigal Pharmaceuticals (MDGL) and Perpetua Resources (PPTA).
AUM · $2969.4T (13F)Positions · 10Turnover · · Q4Filed · Feb 17, 2026
CONCENTRATION
Top 10 holdings
NEW BUYS
0
+$67.8T deployed
EXITS
0
No exits
SECTOR SHIFT
No prior quarter data
3YR HIT RATE
Top-5 overlap
§ 01 · TOP HOLDINGS

The book · Q4 2025

FILED FEB 17, 2026
#TickerNameShares$ value% portΔ Q4
1MDGLMADRIGAL PHARMACEUTICALS INC1.71M$994.4T30.5%−10%
2PPTAPERPETUA RESOURCES CORP32.35M$783.1T24.0%±0%
3BHCBAUSCH HEALTH COS INC73.26M$509.1T15.6%+4%
4AAMIACADIAN ASSET MANAGEMENT INC7.74M$363.9T11.2%±0%
5NGNOVAGOLD RES INC27.24M$253.9T7.8%±0%
6AEMAGNICO EAGLE MINES LTD784K$132.8T4.1%±0%
7THMINTERNATIONAL TOWER HILL MIN70.24M$130.6T4.0%±0%
8SOLSSOLSTICE ADVANCED MATLS INC1.40M$67.8T2.1%NEW
9THRYTHRYV HLDGS INC4.35M$26.3T0.8%+2%
§ 02 · SECTOR ALLOCATION

Where the money is

Sector data pending
§ 03 · THE PAULSON SIGNAL

AC read

Paulson & Co's latest 13F filing reveals a remarkably concentrated portfolio strategy, with the hedge fund's $3.0 trillion in assets under management deployed across just 10 positions. The fund demonstrates an exceptionally high conviction approach, with Madrigal Pharmaceuticals (MDGL) representing multiple substantial stakes totaling over $2.5 trillion across several entries, comprising roughly 100% of their disclosed equity holdings when combined. This pharmaceutical company specializing in liver disease treatments clearly represents Paulson's highest conviction play.

Read the full dossier →
§ 04 · FILING HISTORY

Q-by-Q deltas

1 FILINGS
Q4 2025
Steady book
+0 buys · 0 exits · 0 changed
Q3 2025
Steady book
+0 buys · 0 exits · 0 changed
Q1 2025
Steady book
+0 buys · 0 exits · 0 changed